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Abstract Limited information exists about the prevalence, management, and outcomes of interme-
diate-high risk patientswith acute pulmonary embolism (PE). In a prospective cohort study,
we evaluated consecutive patients with intermediate-high risk PE at a large, tertiary,
academic medical center between January 1, 2015 and March 31, 2019. Adjudicated
outcomes included PE-related mortality and a complicated course through 30 days after
initiation of PE treatment. Repeat systolic blood pressure (SBP), heart rate (HR), brain
natriuretic peptide (BNP), and cardiac troponin I (cTnI) measurements, and echocardiog-
raphy were performed within 48hours after diagnosis. Among 1,015 normotensive
patients with acute PE, 97 (9.6%) had intermediate-high risk PE. A 30-day complicated
course and 30-day PE-related mortality occurred in 23 (24%) and 7 patients (7.2%) with
intermediate-high risk PE. Seventeen (18%) intermediate-high risk patients received
reperfusion therapy. Within 48hours after initiation of anticoagulation, normalization of
SBP, HR, cTnI, BNP, and echocardiography occurred in 82, 86, 78, 72, and 33% of survivors
with intermediate-high risk PEwho did not receive immediate thrombolysis. A complicated
course between day 2 and day 30 after PE diagnosis for the patients who normalized SBP,
HR, cTnI, BNP, and echocardiography measured at 48hours occurred in 2.9, 1.4, 4.5, 3.3,
and 14.3%, respectively. Intermediate-high risk PE occurs in approximately one-tenth of
patients with acute symptomatic PE, and is associated with high morbidity and mortality.
Normalization of HR 48hours after diagnosis might identify a group of patients with a very
low risk of deterioration during the first month of follow-up.
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Hemodynamically unstable acute pulmonary embolism (PE)
is a cardiovascular emergency, associated with high risk of
death from worsening right ventricle (RV) failure and car-
diogenic/obstructive shock, with an in-hospital mortality
rate of>15%.1–3 For normotensive patients diagnosed with
PE, risk stratification should aim to identify the group of
patients deemed as having a high risk for a PE-related
complicated course (intermediate-high risk PE) that might
benefit from intensive monitoring or escalation of therapy.4
Prior investigations from existing PE registries have pro-
vided some important insights into the use of prognostic
tools to identify patients with intermediate-high risk PE.5,6
According to the European Society of Cardiology (ESC) guide-
lines, normotensive PE patients with a positive prognostic
score (i.e., Pulmonary Embolism Severity Index [PESI], sim-
plified PESI [sPESI]), and evidence of RV dysfunction by
elevated cardiac biomarkers (i.e., cardiac troponin test) and
imaging should be classified into an intermediate-high risk
category.4 However, studies have shown conflicting data
regarding the prognostic significance of intermediate-high
risk PE.7,8 While one study found the proportion of compli-
cations for patients in the intermediate-high risk group to be
significantly higher than in the intermediate-low risk group
(17.5 vs. 10%),7 another study did not confirm these find-
ings.8 There remains limited contemporary information
about the epidemiology, management, and outcomes of
patients with intermediate-high risk PE. Further, there is
uncertainty about the subgroup of patients with intermedi-
ate-high risk PEwho aremore likely to deteriorate, and hence
may benefit from reperfusion.
Accordingly, we conducted a prospective cohort study to
determine the prevalence, treatment patterns, and associat-
ed outcomes for patients with intermediate-high risk PE in
routine clinical practice, and to explore the markers of early
response to anticoagulant therapy.
Methods
Study Design
Consecutive normotensive patients with a diagnosis of acute
PE between January 1, 2015 and March 31, 2019 were
approached for enrollment in a prospective study. All
patients provided informed consent for their participation
in the study in accordance with the requirements of the
ethics committee of the hospital, and the human subjects
committee approved this study.
Patients, Setting, and Eligibility Criteria
Patients were recruited from the emergency department of
Ramón y Cajal Hospital, Madrid, Spain. Eligibility for this
study required that patients have acute symptomatic PE
confirmed by either a contrast-enhanced PE protocol helical
chest computed tomography (CT),9 a high probability venti-
lation–perfusion scan result according to the criteria of the
Prospective Investigation of Pulmonary Embolism Diagno-
sis,10 or a lower limb venous compression ultrasonography
positive for a proximal deep vein thrombosis in patients with
inconclusive ventilation–perfusion scans.11
Definition of Intermediate-High Risk PE
We defined intermediate-high risk PE as the presence of
hemodynamic stability (systolic blood pressure [SBP] 
90mm Hg), a positive sPESI, and concomitant echocardio-
graphic RV dysfunction, and positive cardiac troponin.4
Calculation of the sPESI
Using the baseline data collected at the time of PE diagnosis,
investigators prospectively determined the sPESI.12 The sPESI
categorized patients with none of the variables present as
negative, and thosewith at least one factor present as positive.
Transthoracic Echocardiography
The study required that patients undergo transthoracic
echocardiography within 12 hours after diagnosis of PE.
Trained and certified local cardiologists interpreted
each echocardiogram. The study defined echocardio-
graphic RV dysfunction as the presence of at least two
of the following: dilatation of the RV (end-diastolic diam-
eter>30mm from the parasternal view or the RV appear-
ing larger than the left ventricle from the subcostal or
apical view), hypokinesis of the RV free wall (any view),
and estimated systolic pulmonary artery pressure over
30mm Hg.13,14
Cardiac Biomarker Determinations
The Hospital Universitario Ramon y Cajal-IRYCIS Biobank
processed the biological samples. The laboratory personnel,
blinded to the patients’ baseline characteristics and clinical
outcome, measured cardiac troponin I (cTnI) levels quanti-
tatively by using a microparticle enzyme immunoassay
(MEIA) (Abbot, United States). The study defined cTnI con-
centrations of>0.05 ng/mL as indicative of myocardial inju-
ry (cTnI positive).13,15 Brain natriuretic peptide (BNP) levels
were measured by the MEIA system immunoassay in an
Architect i2000 analyzer (Abbott). The study protocol de-
fined BNP concentrations of >100 pg/mL as indicative of
cardiac myocyte stretch (BNP positive).16
Study Endpoints and Outcome Measures
The study used PE-related mortality and a “complicated
course” as the study endpoints. Investigators determined
survival status by conducting patient or proxy interviews,
and/or hospital chart review. Fatal PE was defined as death
from PE confirmed by autopsy or death following a clinically
severe PE, either initially or shortly after an objectively
confirmed recurrent event, in the absence of any alternative
diagnosis. A “complicated course” was defined as a com-
posite of PE-related death, hemodynamic collapse (defined
as need for cardiopulmonary resuscitation, SBP<90mm Hg
for at least 15minutes, need for vasopressor administration,
or need for reperfusion with thrombolytic therapy or
surgery), or recurrent PE within the 30 days of follow-up.
Two investigators (R.M. and F.L.) adjudicated all serious
adverse events.
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We defined major bleeding episodes as those that re-
quired a transfusion of at least 2 units of blood, were
retroperitoneal, spinal or intracranial, or were fatal.
Treatment and Follow-Up
Between January 1, 2015 and January 1, 2018, clinicians
managed patients according to their own practice (i.e., no
standardization of treatment). After January 1, 2018, a
Pulmonary Embolism Response Team coordinated clinical
care of patients with high- and intermediate-high risk PE.
The study recorded information related to patient outcomes
through 30 days after the diagnosis of the acute PE.
Statistical Analyses
The study reported categorical data as proportions and
continuous data as mean standard deviation or median
(first–third interquartile range). We used unpaired two-
tailed t-tests or theMann–WhitneyU test (for those variables
found not to followa normal distribution) for comparisons in
the distributions of continuous variables between interme-
diate-high risk versus low- and intermediate-low risk PE
patients, and chi-squared or Fisher’s exact tests to compare
the categorical data between the two groups. We also used
these tests to explore differences between the patients with
intermediate-high risk PE who did and did not receive any
kind of reperfusion therapies (i.e., systemic thrombolysis,
local thrombolysis, percutaneous procedures, and surgical
embolectomy).
For survivors who did not receive immediate (i.e., at the
time of PE diagnosis) thrombolysis, repeat SBP, heart rate
(HR), cTnI, and BNP measurements, and echocardiography
were performed within 48hours after initiation of anti-
coagulation. Assessment of vital signs was done by the
study cardiologists just before the repeat echocardiogram.
Normalization of prognostic tests was defined as an in-
crease in SBP>100mm Hg, a decrease in HR<100 beats
per minute, a decrease in cTnI levels to  0.05 ng/mL, a
decrease in BNP levels to  100 pg/mL, and absence of
echocardiographic RV dilation and dysfunction. For each
test risk subgroup (i.e., negative vs. positive), the propor-
tion of patients with 30-day adverse outcomes was deter-
mined. To assess the test and performance characteristics
of each test negative versus positive categories, we esti-
mated sensitivity, specificity, and positive and negative
predictive values.
Analyses were performed using SPSS, version 23.0 for the
personal computer (SPSS Inc., Chicago, Illinois, United
States). All hypothesis tests were two-sided, with a signifi-
cance level of 0.05.
Results
We enrolled 1,015 normotensive patients with acute PE (486
men and 529 women) from January 1, 2015 to March 31,
2019 (►Fig. 1). Overall, 97 patients (9.6%; 95% confidence
interval [CI], 7.8–11.5%) had intermediate-high risk, 571
(56%) patients had intermediate-low risk, and 347 (34%)
had low-risk PE. Patients with intermediate-high risk PE
differed significantly from those with low- and intermedi-
ate-low risk PE in preexisting medical conditions, and in
relevant clinical, physiologic, and laboratory parameters. As
expected, patientswith intermediate-high risk PEwere older
and had more comorbid diseases (immobility, high-risk
sPESI), and signs of clinical severity (tachycardia, hypoxemia,
and hypotension), compared with those with low- or inter-
mediate-low risk PE (►Table 1).
Treatment Patterns
Seventeen (18%; 95% CI, 11–27%) intermediate-high risk
patients received reperfusion therapy (6 patients received
immediate thrombolysis at the time of PE diagnosis, and 11
patients after clinical deterioration). No patient received
surgical or catheter embolectomy. Patients who received
reperfusion were younger than patients who did not receive
reperfusion (5720 vs. 7314 years), and more frequently
presented with chest pain, tachycardia, and hypotension,
compared with intermediate-high risk patients who did not
receive reperfusion (►Table 2). Interestingly, the two treat-
ment groups had similar proportions of male gender, history
of heart failure, chronic obstructive pulmonary disease
Fig. 1 Patient flow diagram. PE, pulmonary embolism.
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(COPD), cancer, recent surgery, history of venous thrombo-
embolism, and immobilization.
Outcomes
Outcomes data were available for all patients through the 30-
day study follow-up. The30-dayall-causemortality rateswere
10% (95% CI, 5.1–18%) in patients with intermediate-high
versus 4.0% (95% CI, 2.9–5.6%) in thosewith low- and interme-
diate-low risk PE. In the intermediate-high risk group, most
deaths (7 of 10 deaths; 70%; 95%CI, 35–93%)were attributable
to PE,while 3 patients (3.1%; 95% CI, 0.6–8.8%) died fromother
causes (cancer 2, and COPD 1). Twenty-three of 97 intermedi-
ate-high risk PE patients (24%; 95% CI, 16–33%) had a compli-
cated course. In addition to the 7 PE-related deaths,
complicated course was due to nonfatal hemodynamic col-
lapsedeterioration in16patients (►Supplementary Table S1).
Two of 97 patients (2.1%; 95% CI, 0.3–7.3%) had recurrent
symptomatic PE (both fatal), and 4 patients (4.1%; 95% CI, 1.1–
10%) suffered a major bleeding episode (retroperitoneal 2,
intracranial 1, and need for transfusion 1).
In the subgroup of patients with intermediate-high risk
PE, PE-related mortality within 30 day of PE diagnosis
occurred in 4 patients (3.2%; 95% CI, 0.9–8.1%) who received
delayed reperfusion (i.e., after clinical deterioration), and in 3
patients (3.8%; 95% CI, 0.8–10.6%) who did not receive
reperfusion. Of the patients who received thrombolysis,
5.9% (1 of 17 patients) had recurrent PE during the 30-day
study follow-up period. Of those who did not receive throm-
bolysis, 1.3% (1 of 80 patients) recurred during follow-up. Of
the patients who received thrombolysis, 12% (2 of 17
Table 1 Patient characteristics (n¼ 1,015)
Intermediate-high risk PE
N¼ 97




Age, y (mean SD) 70.416.2 66.8 16.3 0.04
Age>80 y 28 (30) 166 (18) 0.01
Male gender 43 (44) 443 (48) 0.52
Risk factors for VTE,
Cancera 7 (7.2) 108 (12) 0.24
Recent surgeryb 7 (7.2) 102 (11) 0.24
History of VTE 8 (8.2) 180 (20) < 0.01
Immobilizationc 22 (37) 211 (23) < 0.01
Comorbid diseases
Chronic lung disease 10 (11) 93 (11) 1.00
Chronic heart disease 5 (5.2) 39 (4.2) 0.60
Clinical symptoms and signs at presentation
Syncope 29 (33) 138 (15) < 0.001
Chest pain 43 (36) 413 (45) 0.11
Dyspnea 76 (85) 771 (84) 1.00
Heart rate  110/min 42 (43) 205 (22) < 0.001
Arterial oxyhemoglobin
saturation (SaO2)< 90%
57 (59) 147 (26) < 0.001
SBP<100 mm Hg 8 (8.2) 38 (4.1) 0.07
sPESI12
Low-risk 0 (0) 347 (38) <0.001
High-risk 97 (100) 571 (62) < 0.001
Echocardiography and cardiac biomarkers, n (%)
RV dysfunction 97 (100) 29/24212 <0.001
cTnI>0 ng/mL 97 (100) 115/56420 <0.001
Abbreviations: cTnI, cardiac troponin I; PE, pulmonary embolism; RV, right ventricle; SBP, systolic blood pressure; SD, standard deviation; sPESI,
simplified Pulmonary Embolism Severity Index; VTE, venous thromboembolism.
aActive or under treatment in the last year.
bIn the previous month.
cImmobilized patients defined as nonsurgical patients with limited mobility (i.e., total bed rest with bathroom privileges) for  4 days in the month
prior to PE diagnosis.
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patients) bled during the 30-day study follow-up period. Of
those who did not receive thrombolysis, 2.5% (2 of 80
patients) bled during follow-up.
Response to Anticoagulation
Within 48 hours after initiation of anticoagulation, repeat
SBP, HR, cTnI, and BNPmeasurements, and echocardiography
were obtained in 85 survivors who did not receive immedi-
ate thrombolysis. Of these, 11 (13%; 95% CI, 6.6–22%) experi-
enced a complicated course and 8 (9.4%; 95% CI, 4.2–18%)
died between day 2 and day 30 after PE diagnosis. Overall, 5
patients (5.9%) died from definite or possible PE, 1 (1.2%)
from COPD, and 2 (2.4%) from cancer. One patient had an
episode of (fatal) recurrent PE, and 2 patients had an episode
of nonfatal major bleeding. Normalization of SBP, HR, cTnI,
BNP, and echocardiography occurred in 82, 86, 78, 72, and
33%, respectively (►Table 3).
For the patients who normalized SBP, HR, cTnI, BNP, and
echocardiography measured at 48hours, a complicated
course occurred in 2.9, 1.4, 4.5, 3.3, and 14.3%, respectively
(►Table 3). The sensitivity, specificity, and predictive values
for the tests performed at 48hours for predicting 30-day
adverse events are listed in ►Table 3.
Discussion
In this prospective cohort study, intermediate-high risk PE
occurred in 10% of normotensive patients with acute symp-
tomatic PE, with markedly worse outcomes compared with
those with low- or intermediate-low risk PE. During the first
30 days of follow-up, a complicated course occurred in one-
fourth of the patients, and 30-day PE-related mortality rate
was approximately 7%. Only one-fifth of the patients with
intermediate-high risk PE received thrombolytic therapy,
most of them after clinical deterioration. Normalization of
clinical markers, including HR within 48hours of PE diagno-
sis, identified patients with an uncomplicated course during
the first month of anticoagulant therapy.
Identification of intermediate-high risk PE has evolved
over time. Studies of patients with normotensive PE found
that those with echocardiographic RV dysfunction and myo-
cardial injury had a greater risk of short-term death com-
pared with patients with either echocardiographic RV
dysfunction or elevated troponin levels (or none).17,18
Accordingly, the ESC guidelines defined intermediate-high
risk patients with acute symptomatic PE as those who are
hemodynamically stable, and have myocardial injury and
Table 2 Clinical characteristics of patients with intermediate-high risk PE (n¼ 97) who did or did not receive thrombolysis
Received thrombolysis
N¼ 17




Age, y (mean SD) 56.620.3 73.313.7 < 0.001
Age>80 y 0 (0) 28 (35) < 0.01
Male gender 8 (47) 35 (44) 1.00
Risk factors for VTE,
Cancera 1 (5.9) 6 (7.5) 1.00
Recent surgeryb 1 (5.9) 6 (7.5) 1.00
History of VTE 2 (12) 6 (7.5) 0.63
Immobilizationc 3 (18) 19 (24) 0.75
Comorbid diseases
Chronic lung disease 0 (0) 10 (13) 0.20
Chronic heart disease 0 (0) 5 (6.3) 0.58
Clinical symptoms and signs at presentation
Syncope 4 (24) 25 (31) 0.77
Chest pain 12 (71) 31 (39) 0.03
Dyspnea 13 (76) 63 (79) 1.00
Heart rate  110/min 13 (76) 29 (36) 0.02
Arterial oxyhemoglobin
saturation (SaO2)< 90%
7 (41) 50 (63) 0.17
SBP<100 mm Hg 5 (29) 3 (3.8) < 0.01
Abbreviations: PE, pulmonary embolism; SBP, systolic blood pressure; SD, standard deviation; VTE, venous thromboembolism.
aActive or under treatment in the last year.
bIn the previous month.
cImmobilized patients defined as nonsurgical patients with limited mobility (i.e., total bed rest with bathroom privileges) for  4 days in the month
prior to PE diagnosis.
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RV dysfunction.4 More recent observational studies have
suggested an incremental prognostic value of the association
of markers of RV dysfunction and injury with clinical vari-
ables.6,19 The prevalence of intermediate-high risk in the
study cohort (10%) was lower than in a previous study in
which the prevalence was 30%.8 This discrepancy may be
explained at least in part because the present study used the
combination of a positive sPESI with echocardiographic RV
dysfunction and myocardial injury for identifying the more-
severe intermediate-risk patients with acute PE, as recom-
mended by the 2014 and 2019 ESC guidelines.4,20
The Pulmonary Embolism Thrombolysis (PEITHO) trial
was a randomized, double-blind trial that assessed the
efficacy and safety of tenecteplase in normotensive patients
with RV dysfunction/enlargement on echocardiography or
CT, as well as myocardial injury as indicated by a positive
test for cTnI or troponin T.21 Compared with the 10% 30-day
mortality in our study cohort, short-term death occurred
infrequently in the trial’s placebo arm (3.2%). This finding
might support the requirement of clinical variables in
addition to cardiac biomarkers and imaging testing to
identify the sickest normotensive patients with acute symp-
tomatic PE.
Practice guidelines suggest that most patients with inter-
mediate-high risk PE should receive standard anticoagula-
tion alone,4,22 and guideline-adherentmanagement strongly
correlateswith patient outcomes.23 In this study, only a small
proportion of patients received immediate thrombolytic
















































































































































































































Abbreviations: CI, confidence interval; PE, pulmonary embolism.
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therapy. Since these patients hadmore severe hemodynamic
decompensation comparedwith thosewho received delayed
thrombolysis, future trials should evaluate the efficacy and
safety of reperfusion therapies in intermediate-high risk
patients who have an overwhelming accumulation of prog-
nostic factors indicative of a more marked cardiopulmonary
impairment.
Clinical practice guidelines suggest close monitoring of
patients with intermediate-high risk PE, and prompt treat-
ment if decompensation occurs. However, it is not clear how
long these patients should be monitored, and the optimal
method to assess early response to anticoagulant therapy. In
the PEITHO trial, mean time from enrolment to deterioration
in the placebo arm was 1.81.6 days.21 For this reason, this
study assessed clinical variables, cardiac biomarkers, and
echocardiographywithin 48hours after diagnosis of acute PE
to explore the optimal method to assess response to antico-
agulant treatment. Our results suggest that resolution of
tachycardia might be a reliable tool to identify those patients
with a negligible risk of deterioration within the first few
days. Compared with cardiac biomarker testing and echo-
cardiography, measurement of HR is a simple, inexpensive,
rapid, repeatable, and easily interpretable tool for risk
assessment.
Our findings should be interpreted in the context of our
study design and its limitations. Despite the large number of
normotensive patients with acute PE assessed for this study,
the number of patients with intermediate-high risk PE did
not allow for more precision in our estimates. In the present
study, echocardiograms were done and interpreted by a
limited number of certified cardiologists and thus the results
cannot be necessarily applied to less experienced operators.
The study protocol did not collect information on clot loca-
tion and degree of obstruction in a standardized fashion.
Thus, the study cannot report such information. Further, this
was a single-center study at a large referral center and
treatment-related decisions may not be necessarily reflec-
tive of all other centers.
In conclusion, in this cohort of consecutive patients with
acute PE, intermediate-high risk PE was found in 10% of
normotensive patients. Such patients had markedly worse
outcomes compared with other normotensive patients with
PE, suggesting the need for close monitoring. Assessment of
HRmay be useful to estimate the response to anticoagulation
and the risk of deterioration.
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